8. Bibliographie

1. Buchegger, F., Slosman, D. O., Meier, C., Dupertuis, Y., Mach, J.-P., and Bischof Delaloye, A. La radiothérapie systémique isotopique. Médecine & Hygiène, 2262: 1418-1422, 1999.
2. Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Nelp, W. B., Glenn, S., Fisher, D. R., Porter, B., Matthews, D. C., Gooley, T., and al., e. Phase II trial of ¹³¹I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet, 346: 336, 1995.
3. Otte, A., Jermann, E., Behe, M., Goetze, M., Bucher, H. C., Roser, H. W., Heppeler, A., Mueller-Brand, J., and Maecke, H. R. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med, 24: 792-795, 1997.
4. Buchegger, F., Roth, A., Allal, A., Dupertuis, Y. M., Slosman, D. O., Bischof Delaloye, D. O., and Mach, J.-P. Radioimmunotherapy of colorectal cancer liver metastases: combination with radiotherapy. Ann N Y Acad Sci, 910: 263-270, 2000.
5. Buchegger, F., Allal, A. S., Roth, A., Papazyan, J.-P., Dupertuis, Y., Mirimanoff, R.-O., Gillet, M., Pèlegrin, A., Mach, J.-P., and Slosman, D. O. Combined radioimmunotherapy and radiotherapy of liver metastases. Anticancer Res, 20, 2000.
6. Shields, A. F., Mankoff, D. A., Link, J. M., Graham, M. M., Eary, J. F., Kozawa, S. M., Zheng, M., Lewellen, B., Lewellen, T. K., Grierson, J. R., and Krohn, K. A. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med, 39: 1757-1762, 1998.
7. Sherr, C. J. Cancer cell cycles. Science, 274: 1672-1677, 1996.
8. Nigg, E. A. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. BioEssays, 17: 471-480, 1995.
9. Murray, A. W. Creative blocks: cell cycle checkpoints and feedback controls. Nature, 359: 599-604, 1992.
10. Hardcastle, I. R., Golding, B. T., and Griffin, R. J. Designing inhibitors of cyclin-dependent kinases. Annu Rev Pharmacol Toxicol, 42: 325-348, 2002.
11. Pines, J. Cyclins and cyclin-dependent kinases: take your partners. Trends Biochem Sci, 18: 195-197, 1993.
12. Sherr, C. J. G1 phase progression: cycling on cue. Cell, 79: 551-555, 1994.
13. Nurse, P. Ordering S phase and M phase in the cell cycle. Cell, 79: 547-550, 1994.
14. Morgan, D. O. Principles of CDK regulation. Nature, 374: 131-134, 1995.
15. Galaktionov, K., Chen, X., and Beach, D. CDC25 cell-cycle phosphatase as a target of c-myc. Nature, 382: 511-517, 1996.
16. Hunter, T. and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
17. Hall, M. and Peters, G. Genetic alterations of cyclins, cyclin-dependent kinases, and CDK inhibitors in human cancer. Adv Cancer Res, 68: 67-108, 1996.
18. Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J., and Livingston, D. M. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell, 73: 487-497, 1993.
19. Nevins, J. R. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science, 258: 424-429, 1992.
20. Fagan, R., Flint, K. J., and Jones, N. Phosphorylation of E2F-1 modulates its interaction with the retinoblastoma gene product and the adenoviral E4 19 KDa protein. Cell, 78: 799-811, 1994.
21. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
22. Zhu, X., Ohtsubo, M., Böhmer, R. M., Roberts, J. M., and Assoian, P. K. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-CDK2, and phosphorylation of the retinoblastoma protein. J Cell Biol, 133: 391-403, 1996.
23. Knoblich, J. A., Sauer, K., Jones, L., Richardson, H., Saint, R., and Lehner, C. F. Cyclin E controls S phase progression and its down-regulation during Drosophila embryogenesis is required for the arrest of cell proliferation. Cell, 77: 107-120, 1994.
24. Won, K. A. and Reed, S. I. Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. EMBO J, 15: 4182-4193, 1996.
25. Pagano, M., Pepperkok, R., Lukas, J., Baldin, V., Ansorge, W., Bartek, J., and Draetta, G. Cyclin A is required at two points in the human cell cycle. EMBO J, 11: 961-971, 1992.
26. Krek, W., Xu, G., and Livingston, D. M. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell, 83: 1149-1158, 1995.
27. Ohtsubo, M. and Roberts, J. M. Cyclin-dependent regulation of G1 in mammalien fibroblasts. Science, 259: 1908-1912, 1993.
28. King, R. W., Jackson, P. K., and Kirschner, M. W. Mitosis in transition. Cell, 79: 563-571, 1994.
29. Nigg, E. A. Cellular substrates of p34CDC2 and its companion cyclin-dependent kinases. Trends Biol, 3: 296-301, 1993.
30. Fisher, R. P. and Morgan, D. O. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell, 78: 713-724, 1994.
31. Solomon, M. J., Harper, J. W., and shuttleworth, J. CAK, the p34^CDC2 activating kinase, contains a protein identical or closely related to p40^MO15. EMBO J, 12: 3133-3240, 1993.
32. Morgan, D. O. and De Bondt, H. L. Protein kinase regulation: insights from crystal structure analysis. Curr Opin Cell Biol, 6: 239-246, 1994.
33. Mäkelä, T. P., Tassan, J. P., Nigg, E., Frutiger, S., Hughes, G. J., and Weinberg, R. A. A cyclin associated with CDK-activating kinase MO15. Nature, 371: 254-257, 1994.
34. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature, 366: 701-704, 1993.
35. Zhang, H., Hannon, G. J., and Beach, D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev, 8: 1750-1758, 1994.
36. Li, R., Waga, S., Hannon, G. J., Beach, D., and Stillman, B. Differential effects by p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature, 371: 534-537, 1994.
37. Elledge, S. J. and Harper, J. W. CDK inhibitors: on the threshold of checkpoints and development. Curr Opin Cell Biol, 6: 847-852, 1994.
38. Nourse, J., Firpo, E., Flanagan, W. M., Coats, S., Polyak, K., Lee, M. H., Massague, J., Crabtree, G. R., and Roberts, J. M. Interleukin-2-mediated elimination of the p27KIP1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature, 372: 570-573, 1994.
39. Polyak, K., Lee, M. H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., and Massague, J. Cloning of p27^KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
40. Coats, S., Flanagan, W. M., Nourse, J., and Roberts, J. M. Requirement of p27^KIP1 for restriction point control of the fibroblast cell cycle. Science, 272: 877-880, 1996.
41. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366: 704-707, 1993.
42. Hannon, G. J. and Beach, D. p15^INK4B is a potential effector of TGF-B-induced cell cycle arrest. Nature, 371: 257-261, 1994.
43. Hara, E., Smith, R., Parry, D., Tahara, H., Stone, S., and Peters, G. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol, 16: 859-867, 1996.
44. Lane, D. P. Cancer. p53, guardian of the genome. Nature, 358: 80-83, 1992.
45. Van Meir, E. G., Roemer, K., Diserens, A.-C., Kikuchi, T., Rempel, S. A., Haas, M., Su Huang, H.-J., Friedmann, T., De Tribolet, N., and Cavenee, W. K. Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells. Proc Natl Acad Sci USA, 92: 1008-1012, 1995.
46. Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., and Hannon, G. J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature, 377: 552-557, 1995.
47. White, E. Life, death and the pursuit of apoptosis. Genes Dev, 10: 1-15, 1996.
48. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., Devilee, P., and al., e. Mutations in the p53 gene occur in diverse human tumour types. Nature, 342: 705-708, 1989.
49. Van Meyel, D. J., Ramsay, D. A., Casson, A. G., Keeney, M., Chambers, A. F., and Cairncross, J. G. p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J Natl Cancer I, 86: 1011-1017, 1994.
50. Ali, I. U., Schweitzer, J. B., Ikejiri, B., Saxena, A., Robertson, J. T., and Oldfield, E. H. Heterogeneity of subcellular localization of p53 protein in human glioblastomas. Cancer Res, 54: 1-5, 1994.
51. Yount, G. L., Haas-Kogan, D. A., Vidair, C. A., Haas, M., Dewey, W. C., and Israel, M. A. Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells. Cancer Res, 56: 500-506, 1996.
52. Cook, P. R. The organization of replication and transcription. Science, 284: 1790-1795, 1999.
53. Liu, L. F. and Wan, g. J. C. Supercoiling of the DNA template during transcription. Proc Natl Acad Sci U S A, 84: 7024-7027, 1987.
54. Jiricny, J. Replication errors: cha(lle)nging the genome. EMBO J, 17: 6427-6436, 1998.
55. Lindahl, T. and Wood, R. D. Quality control by DNA repair. Science, 286: 1897-1905, 1999.
56. Wallace, S. S. Enzymatic processing of radiation-induced free radical damage in DNA. Radiat Res, 1998.
57. Kunz, B. A. Inhibitors of thymine nucleoside biosynthesis: antimetabolites that provoke genetic change via primary non-DNA targets. Mutat Res, 355: 129-140, 1996.
58. Dunlap, R. B., Harding, N. G. L., and Huennekens, F. M. Thymidylate synthetase from amethopterin resistant Lactobacillus casei. Biochemistry, 10: 88-97, 1971.
59. Prusoff, W. H. Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochem Biophy Acta, 32: 295-296, 1959.
60. Djordjevic, B. and Szybalski, W. Genetics of human cell lines. III. Incorporation of 5-bromo and 5-iododeoxyuridine into the deoxyuribonucleic acid of human cells and its effect on radiation sensitivity. J Exp Med, 112: 509-531, 1960.
61. Hoshino, T., Ito, S., Asai, A., Shibuya, M., Prados, M. D., Dodson, B. A., Davis, R. L., and Wilson, C. B. Cell kinetic analysis of human brain tumors by in situ double labelling with bromodeoxyuridine and iododoxyuridine. Int J Cancer, 50: 1-5, 1992.
62. Rodriguez, R., Ritter, M. A., Fowler, J. F., and Kinsella, T. J. Kinetices of cell labeling and thymidine replacement after continuous infusion of halogenated pyrimidines in vivo. Int J Radiat Oncol Bio Phys, 29: 105-113, 1994.
63. Eidinoff, M. L., Cheong, L., and Rich, M. A. Incorporation of unnatural pyrimidine base into deoxyribonucleic acid of mammalian cells. Science, 129: 1550-1551, 1959.
64. Morris, N. R. and Cramer, J. W. DNA synthesis by mammalian cells inhibited in culture by 5-iodo-2'-deoxyuridine. Mol Pharmacol, 2: 1-9, 1966.
65. Bresnick, E. and Thompson, U. B. Properties of deoxythymidine kinase partially purified from animal tumors. J Biol Chem, 240: 3967-3974, 1965.
66. Commerford, S. L. and Joel, D. D. Iododeoxyuridine administered to mice is de-iodinated and incorporated into DNA primarily as thymidylate. Biochem Bioph Res Co, 86: 112-118, 1979.
67. Garrett, C., Wataya, Y., and Santi, D. V. Thymidylate synthetase. Catalysis of dehalogenation of 5-bromo- and 5-iodo-2'-deoxyuridylate. Biochemistry, 18: 2798-2804, 1979.
68. Commerford, S. L. Biological stability of IUdR labeled with ¹²⁵I after incorporation into the DNA of the mouse. Nature, 206: 949-950, 1965.
69. Iliakis, G. and Nüsse, M. Evidence that repair and expression of potentially lethal damage cause the variations in cell survival after x irradiation observed through the cell cycle in Ehrlich ascites tumor cells. Radiat Res, 95: 87-107, 1983.
70. O'Donoghue, J. A. Strategies for selective targeting of Auger electron emitters to tumor cells. J Nucl Med, 37 (Suppl): 3S-6S, 1996.
71. Foulon, C. F., Zhang, Y. Z., Adelstein, S. J., and Kassis, A. I. Instantaneous preparation of radiolabeled 5-iodo-2'-deoxyuridine. Appl Radiat Isot, 46: 1039-1046, 1995.
72. Foulon, C. F., Adelstein, S. J., and Kassis, A. I. Kit formulation for the preparation of radiolabeled Iododeoxyuridine by demetallation. J Nucl Med, 37 (Suppl): 1S-3S, 1996.
73. Tijuvajev, J. G., Macapinlac, H. A., Daghighian, F., Scott, A. M., Ginos, T. Z., Finn, R. D., Kothari, P., Desai, K., Zhang, J., Beattie, B., Graham, M., Larson, S. M., and Blasberg, R. G. Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. J Nucl Med, 35: 1407-1417, 1994.
74. Hofer, K. G. and Hughes, W. L. Radiotoxicity of intracellular tritium,¹²⁵Iodine and ¹³¹Iodine. Radiat Res, 47: 94-109, 1971.
75. Chan, P. C., Lisco, E., Lisco, H., and Adelestein, S. J. The radiotoxicity of iodine-125 in mammalian cells II: A comparative study on cell survival and cytogenetic responses to 125IUdR, 131IUdR and 3HTdR. Radiat Res, 67: 332-343, 1976.
76. Charlton, D. E. and Booz, J. A Monte Carlo treatment of the decay of ¹²⁵I. Radiat Res, 87: 10-23, 1981.
77. Painter, R. B., Young, B. R., and Burk, H. J. Non-repairable strand breaks induced by ¹²⁵I incorporated into mammalian DNA. Proc Natl Acad Sci USA, 71: 4836-4838, 1974.
78. Makrigiorgos, G. M., Berman, R. M., Baranowska-Kortylewisz, J., Bump, E., Humm, J. L., Adelstein, S. J., and Kassis, A. I. DNA damage produced in V79 cells by DNA-incorporated iodine-123: a comparison with iodine-125. Radiat Res, 129: 309-314, 1992.
79. Kassis, A. I., Sastry, K. S. R., and Adelstein, S. J. Kinetics of uptake, retention and radiotoxicity of ¹²⁵IUdR in mammalian cells: implications of localized energy deposition by Auger processes. Radiat Res, 109: 78-89, 1987.
80. Kassis, A. I., Fayad, F., Kinsey, B. M., Sastry, K. S. R., Taube, R. A., and Adelstein, S. J. Radiotoxicity of ¹²⁵I in mammalian cells. Radiat Res, 111: 305-318, 1987.
81. Narra, V. R., Howell, R. W., Harapanhalli, R. S., Sastry, K. S. R., and Rao, D. V. Radiotoxicity of some iodine-123, iodine-125 and iodine-131-labeled compounds in mouse testes: implications for radiopharmaceutical design. J Nucl Med, 33: 2196-2201, 1992.
82. Warters, R. L., Hofer, K. G., Harris, C. R., and Smith, J. M. Radionuclide toxicity in cultured mammalian cells: elucidation of the primary site of radiation damage. Curr Top Radiat Res Q, 12: 389-407, 1977.
83. Humm, J. L., Howell, R. W., and Rao, D. V. Dosimetry of Auger-electron-emitting radionuclides: report no. 3 of AAPM Nuclear Medicine Task Group No. 6. Med Phys, 21: 1901-1915, 1994.
84. Sastry, K. S. R. and Rao, D. V. Dosimetry of low energy electrons. In: D. V. Rao, R. Chandra, and M. C. Gradham (eds.), Physics of Nuclear Medicine: Recent Advances, Medical Physics No. 10, American Association of Physicists in Medicine, pp. 169-208. Woodbury, NY: American Institute of Physics, 1984.
85. Makrigiorgos, G. M., Kassis, A. I., Baranowska-Kortylewicz, J., McElvany, K. D., Welch, M. J., Sastry, K. S., and Adelstein, S. J. Radiotoxicity of 5-[¹²³I]iodo-2'-deoxyuridine in V79 cells: a comparision with 5-[¹²⁵I]iodo-2'-deoxyuridine. Radiat Res, 118: 532-544, 1989.
86. Blasberg, R. G., Roelcke, U., Weinreich, R., Beattie, B., von Ammon, K., Yonekawa, Y., Landolt, H., Guenther, I., Crompton, N. E. A., Vontobel, P., Missimer, J., Maguire, R. P., Koziorowski, J., Knust, E. J., Finn, R. D., and Leenders, K. L. Imaging brain tumor proliferative activity with [¹²⁴I]iododeoxyuridine. Cancer Res, 60: 624-635, 2000.
87. Klecker, R. W. J., Jenkins, J. F., Kinsella, T. J., Fine, R. L., Strong, J. M., and Collins, J. M. Clinical pharmacology of 5-iodo-2'-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation. Clin Pharmacol Ther, 38: 45-51, 1985.
88. Tjuvajev, J., Muraki, A., Ginos, J., Koutcher, J., Ballon, D., Beattie, B., Finn, R., and Blasgerg, R. Iododeoxyuridine uptake and retention as a measure of tumor growth. J Nucl Med, 34: 1152-1162, 1993.
89. Bagshawe, K. D., Sharma, S. K., Southall, P. J., Boden, J. A., Boxer, G. M., Patridge, T. A., Antoniw, P., and Pedley, R. B. Selective uptake of toxic nucleoside (¹²⁵IUdR) by resistant cancer. Br J Radiol, 64: 37-44, 1991.
90. Humm, J. L., Bagshawe, K. D., Sharma, S. K., and Boxer, G. Tissue dose estimates following the selective uptake of ¹²⁵IUdR and other radiolabelled thymidine precursors in resistant tumors. Br J Radiol, 64: 45-49, 1991.
91. Prusoff, W. H. A review of some aspects of 5-125I-iododeoxyuridine and azauridine. Cancer Res, 23: 1246-1259, 1963.
92. Mariani, G., Cei, A., Collecchi, P., Baranowska-Kortylewicz, J., Vanden Abbeele, A. D., Di Luca, L., Di Stefano, R., Viacava, P., Ferdeghini, E. M., Di Sacco, S., Salvadori, P. A., Bevilacqua, G., Adelstein, S. J., Mosca, F., and Kassis, A. I. Tumor targeting in vivo and metabolic fate of 5-(iodine-125)iodo-2'-deoxyuridine following intratumoral injection in patients with colorectal cancer. J Nucl Med, 34: 1175-1183, 1993.
93. Kassis, A. I., Wen, P. Y., Van den Abbeele, A. D., Baranowska-Kortylewicz, J., Makrigiorgos, G. M., Metz, K. R., Matalka, K. Z., Cook, C. U., Sahu, S. K., Black, P. M., and Adelstein, S. J. 5-[¹²⁵I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats. J Nucl Med, 39: 1148-1154, 1998.
94. Kassis, A. I. and Adelstein, S. J. Preclinical animal studies with radioiododeoxyuridine. J Nucl Med, 37(Suppl): 10S-12S, 1996.
95. Kassis, A. I., Adelstein, S. J., and Mariani, G. Radiolabeled nucleoside analogs in cancer diagnosis and therapy. Q J Nucl Med, 40: 301-319, 1996.
96. Kassis, A. I., Van den Abbeele, A. D., Wen, P. Y. C., Baranowska-Kortylewicz, J., Aaronson, R. A., DeSisto, W. C., Lampson, L. A., Black, P. M., and Adelstein, S. J. Specific uptake of the Auger electron-emitting thymidine analogue 5-[¹²³I/¹²⁵I]iodo-2'-deoxyuridine in rat brain tumors: Diagnostic and therapeutic implications in humans. Cancer Res, 50: 5199-5203, 1990.
97. Kassis, A. I., Tumeh, S. S., Wen, P. Y. C., Baranowska-Kortylewicz, J., Van den Abbeele, A. D., Zimmerman, R. E., Carvalho, P. A., Garada, B. M., DeSisto, W. C., Bailey, N. O., Castronovo, F. P. J., Mariani, G., Black, P. M., and Adelstein, S. J. Intratumoral administration of 5-[¹²³I]iodo-2'-deoxyuridine in a patient with a brain tumor. J Nucl Med, 37 (Suppl): 19S-22S, 1996.
98. Kinsella, T. J., Collins, J., Rowland, J., Klecker, R. J., Wright, D., Katz, D., Steinberg, s. M., and Glatstein, E. Pharmacology and Phase I/II study of continous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme. J Clin Oncol, 6: 871-879, 1988.
99. Phillips, T. L., Levin, V. A., Ahn, D. K., Gutin, P. H., Davis, R. L., Wilson, C. B., Prados, M. D., Wara, W. M., and Flam, M. S. Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study. Int J Radiat Oncol Biol Phys, 21: 709-714, 1991.
100. Leibel, S. A., Scott, C. B., and Loeffler, J. S. Contemporary approaches to the treatment of malignant gliomas with radiation therapy. Semin Oncol, 21: 198-219, 1994.
101. MacDonald, D. R. Low-grade gliomas, mixed gliomas and oligodendrogliomas. Semin Oncol, 21: 236-248, 1994.
102. Brown, J. M., Goffinet, D. R., Cleaver, J. E., and Kallman, R. F. Preferential radiosensitization of mouse sarcoma relative to normal skin by chronic intra-arterial infusion of halogenated pyrimidine analogs. J Natl Cancer Inst, 47: 75-89, 1971.
103. Benson, A. B. I., Trump, D. L., Cummings, K. B., and Fischer, P. H. Modulation of 5-iodo-2'-deoxyuridine metabolism and cytotoxicity in human bladder cancer cells by fluoropyrimidines. Biochem Pharmacol, 34: 3925-3931, 1985.
104. Lawrence, T. S., Davis, M. A., McKeever, P. E., Maybaum, J., Stetson, P. L., Normolle, D. P., and Ensminger, W. D. Fluorodeoxyuridine-mediated modulation of iododeoxyuridine incorporation and radiosensitization in human colon cancer cells in vitro and in vivo. Cancer Res, 51: 3900-3905, 1991.
105. Mancini, W. R., Stetson, P. L., Lawrence, T. S., Wagner, J. G., Greenberg, H. S., and Ensminger, W. D. Variability of 5-bromo-2'-deoxyuridine incorporation into DNA of human glioma cell lines and modulation with fluoropyrimidines. Cancer Res, 51: 870-874, 1991.
106. Kassis, A. I., Guptill, W. E., Taube, R. A., and Adelstein, S. J. Radiotoxicity of 5-[¹²⁵I]iodo-2'-deoxyuridine in mammalian cells following treatment with 5-fluoro-2'-deoxyuridine. J Nucl Biol Med, 35: 167-173, 1991.
107. Mester, J., De Goeij, K., and Sluyser, M. Modulation of [5-¹²⁵I]iododeoxyuridine incorporation into tumour and normal tissue DNA by methotrexate and thymidylate synthase inhibitors. Eur J Cancer, 32A: 1603-1608, 1996.
108. Kassis, A. I., Dahman, B. A., and Adelstein, S. J. In vivo therapy of neoplastic meningitis with methotrexate and 5-[¹²⁵I]iodo-2-deoxyuridine. Acta Oncol, 39: 731-737, 2000.
109. Dupertuis, Y. M., Vazquez, M., Mach, J. P., De Tribolet, N., Pichard, C., Slosman, D. O., and Buchegger, F. Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine. Cancer Res, 61: 7971-7977, 2001.
110. Buchegger, F., Vieira, J. M., Blaeuenstein, P., Dupertuis, Y. M., Schaffland, A. O., Grannavel, C., De Tribolet, N., Slosman, D. O., and Bischof Delaloye, A. Preclinical Auger and gamma radiation dosimetry for fluorodeoxyuridine-enhanced tumour proliferation scintigraphy with [(123)I]iododeoxyuridine. Eur J Nucl Med Mol Imaging, 30: 239-246, 2003.
111. Xiao, W.-H., Dupertuis, Y. M., Mermillod, B., Sun, L.-Q., De Tribolet, N., and Buchegger, F. Unlabelled iododeoxyuridine increases the cytotoxicity and incorporation of ¹²⁵I-iododeoxyuridine in 2 human glioblastoma cell lines. Nucl Med Commun, 21: 947-953, 2000.
112. Kassis, A. I., Adelstein, S. J., Haydock, C., and Sastry, K. S. Radiotoxicity of 75Se and 35S: theory and application to a cellular model. Radiat Res, 84: 407-425, 1980.
113. Vaidyanathan, G., Larsen, R. H., and Zalutsky, M. R. 5-(²¹¹At)Astato-2'-deoxyuridine and alpha-particle-emitting endoradiotherapeutic agent undergoing DNA incorporation. Cancer Res, 56: 1204-1209, 1996.
114. Dupertuis, Y. M., Xiao, W.-H., De Tribolet, N., Pichard, C., Slosman, D. O., Bischof Delaloye, A., and Buchegger, F. Unlabeled iododeoxyuridine increases the rate of uptake of [¹²⁵I]iododeoxyuridine in human xenografted glioblastomas. Eur J Nucl Med, 29: 499-505, 2002.
115. Dupertuis, Y. M., Buchegger, F., and Pichard, C. A balanced deoxyribonucleoside mixture increased the rate of DNA incorporation of 5-[¹²⁵I]-Iodo-2'-deoxyuridine in glioblastoma cells. Cancer Biother Radiopharm, 18: 7-16, 2003.
116. Mosmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays. J Immunol Methods, 65: 55-63, 1983.
117. Denizot, F. and Lang, R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods, 89: 271-277, 1986.
118. Perez, L. A., Dombkowski, D., Efird, J., Preffer, F., and Suit, H. D. Cell proliferation kinetics in human tumor xenografts measured with iododeoxyuridine labeling and flow cytometry: a study of heterogeneity and a comparison between different methods of calculation and other proliferation measurements. Cancer Res, 55: 392-398, 1995.
119. Greene, R. F. and Collins, J. M. Effects of leucovorin on idoxuridine cytotoxicity and DNA incorporation. Cancer Res, 50: 6652-6656, 1990.
120. Schofield, R., Dexter, T. M., Lord, B. I., and Testa, N. G. Comparison of haemopoiesis in young and old mice. Mech Ageing Dev, 34: 1-12, 1986.
121. Blackwell, L. H. and Ledney, G. D. Bone marrow cellularity in normal and polycythemic mice estimated by DNA incorporation of 3H-TdR. Exp Hematol, 10: 514-523, 1982.
122. Sgouros, G., Stabin, M., Erdi, Y., Akabani, G., Kwok, C., Brill, A. B., and Wessels, B. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. Med Phys, 27: 2150-2164, 2000.
123. Buchegger, F., Chalandon, Y., Pelegrin, A., Hardman, N., and Mach, J.-P. Bone marrow dosimetry in rats using direct tissue counting after injection of radio-iodinated intact monoclonal antibodies or F(ab')2 fragments. J Nucl Med, 32: 1414-1421, 1991.
124. Hogan, B., Beddington, R., Costantini, F., and Lacy, E. Manipulating the mouse embryo. Cold Spring Harbor Laboratory Press, 296-298, 1994.
125. Taylor, A. J., Jones, O. W., and Grishaver, M. A. Effect of 5-fluorouracil on the release of thymidine kinase from hepatoma cells in vitro. Cancer Res, 41: 192-196, 1981.
126. Howell, R. W. Radiation spectra for Auger-electron emitting radionuclides: report No. 2 of AAPM Nuclear Medicine Task Group No. 6. Med Phys, 19: 1371-1383, 1992.
127. Ryser, J. E., Blauenstein, P., Remy, N., Weinreich, R., Hasler, P. H., Novak-Hofer, I., and Schubiger, P. A. [⁷⁶Br]Bromodeoxyuridine, a potential tracer for the measurement of cell proliferation by positron emission tomography, in vitro and in vivo studies in mice. Nucl Med Biol, 26: 673-679, 1999.
128. Goddu, S. M., Howell, R. W., and Rao, D. V. Calculation of equivalent dose for Auger electron emitting radionuclides distributed in human organs. Acta Oncol, 35: 909-916, 1996.
129. Stabin, M. G. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med, 37: 538-546, 1996.
130. ICRP publication 53: Radiation dose to patients from radiopharmaceuticals. Ann ICRP, 18: 259-280, 1987.
131. ICRP publication 80: Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53). Ann ICRP, 28: 118, 1998.
132. Goethals, P., Lameire, N., van Eijkeren, M., Kesteloot, D., Thierens, H., and Dams, R. [Methyl-Carbon-11]thymidine for in vivo measurement of cell proliferation. J Nucl Med, 37: 1048-1052, 1996.
133. Eary, J. F., Mankoff, D. A., Spence, A. M., Berger, M. S., Olshen, A., Link, J. M., O'Sullivan, F., and Krohn, K. A. 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res, 59: 615-621, 1999.
134. Mankoff, D. A., Shields, A. F., Link, J. M., Graham, M. M., Muzi, M., Peterson, L. M., Eary, J. F., and Krohn, K. A. Kinetic analysis of 2-[¹¹C]thymidine PET imaging studies: validation studies. J Nucl Med, 40: 614-624, 1999.
135. Kameyama, M., Ishiwata, K., Tsurumi, Y., Itoh, J., Sato, K., Katakura, R., Yoshimoto, T., Hatazawa, J., Ito, M., and Ido, T. Clinical application of ¹⁸F-FUdR in glioma patients--PET study of nucleic acid metabolism. J Neurooncol, 23: 53-61, 1995.
136. Bergström, M., Lu, L., Fasth, K.-J., Wu, F., Bergström-Pettermann, E., Tolmachev, V., Hedberg, E., Cheng, A., and Längström, B. In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker. J Nucl Med, 39: 1273-1279, 1998.
137. Gardelle, O., Roelcke, U., Vontobel, P., Crompton, N. E., Guenther, I., Blauenstein, P., Schubiger, A. P., Blattmann, H., Ryser, J. E., Leenders, K. L., and Kaser-Hotz, B. [76Br]Bromodeoxyuridine PET in tumor-bearing animals. Nucl Med Biol, 28: 51-57, 2001.
138. Armstrong, R. D. and Diasio, R. B. Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine. Cancer Res, 40: 3333-3338, 1980.
139. Harbers, E., Chaudhuri, N. K., and Heidelberger, C. Studies on fluorinated pyrimidines. J Biol Chem, 234: 1255-1262, 1959.
140. Miller, E. M. and Kinsella, T. J. Radiosensitization by fluorodeoxyuridine: effects of thymidylate synthase inhibition and cell synchronization. Cancer Res, 52: 1687-1694, 1992.
141. Canman, C. E., Lawrence, T. S., Shewach, D. S., Tang, H.-Y., and Maybaum, J. Resistance to fluorodeoxyuridine-induced DNA damage and cytotoxicity correlates with an elevation of deoxyuridine triphosphatase activity and failure to accumulate deoxyuridine triphosphate. Cancer Res, 53: 5219-5224, 1993.
142. Port, J. L., Ng, B., Ellis, J. L., Nawata, S., Lenert, J. T., and Burt, M. E. Isolated lung perfusion with FUdR in the rat: pharmacokinetics and survival. Ann Thorac Surg, 62: 848-852, 1996.
143. Morgan, R. J. J., Newman, E. M., Doroshow, J. H., McGonigle, K., Margolin, K., Raschko, J., Chow, W., Somlo, G., Leong, L., Tetef, M., Shibata, S., Hamasaki, V., Caroll, M., Vasilev, S., Akman, S., Coluzzi, P., Wagman, L., Longmate, J., Paz, B., Yen, Y., and Klevecz, R. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis. Cancer Res, 58: 2793-2800, 1998.
144. Wilson, W. L., Bisel, H. F., Krementz, E. T., Lien, R. C., and Prohaska, J. V. Further clinical evaluation of 2'-deoxy-5-fluorouridine (NSC-27640). Cancer Chemother Rep, 51: 85-90, 1967.
145. Serlin, O., Wolkoff, J. S., Amadeo, J. M., and Keehn, R. J. Use of 5-fluorodeoxyuridine (FUDR) as an adjuvant to the surgical management of carcinoma of the stomach. Cancer 1969, 24: 223-228, 1969.
146. Grem, J. L. Fluorinated pyrimidine. In B. A. Chabner and J. M. Collins (eds.) Cancer Chemotherapy: Principles and Practise, Philadelphia: J B Lippincott, 1990: 180-224, 1990.
147. Pomplun, E., Booz, J., Dydejczyk, A., and Feinendegen, L. E. A microdosimetric interpretation of the radiobiological effectiveness of 125I and the problem of quality factor. Radiat Environ Biophys, 26: 181-188, 1987.
148. Rao, D. V., Narra, V. R., Howell, R. W., Lanka, V. K., and Sastry, K. S. Induction of sperm head abnormalities by incorporated radionuclides: dependence on subcellular distribution, type of radiation, dose rate, and presence of radioprotectors. Radiat Res, 125: 89-97, 1991.
149. Haines, G. A., Hendry, J. H., Daniel, C. P., and Morris, I. D. Increased levels of comet-detected spermatozoa DNA damage following in vivo isotopic- or X-irradiation of spermatogonia. Mutat Res, 495: 21-32, 2001.
150. Hoyes, K. P., Nettleton, J. S., Lawson, R. S., and Morris, I. D. Transferrin-dependent uptake and dosimetry of Auger-emitting diagnostic radionuclides in human spermatozoa. J Nucl Med, 39: 895-899, 1998.
151. Daghighian, F., Humm, J. L., Macapinlac, H. A., Zhang, J., Izzo, J., Finn, R., Kemeny, N., and Larson, S. M. Pharmacokinetics and dosimetry of iodine-125-IUdR in the treatment of colorectal cancer metastatic to liver. J Nucl Med, 37 (Suppl): 29S-32S, 1996.
152. Neshasteh-Riz, A., Mairs, R. J., Angerson, W. J., Stanton, P. D., Reeves, J. R., Rampling, R., Owens, J., and Wheldon, T. E. Differential cytotoxicity of [¹²³I]IUdR, [¹²⁵I]IUdR and [¹³¹I]IUdR to human glioma cells in monolayer or spheroid culture: effect of proliferative heterogeneity and radiation cross-fire. Br J Cancer, 77: 385-390, 1998.
153. Neshasteh-Riz, A., Angerson, W. J., Reeves, J. R., Smith, G., Rampling, R., and Mairs, R. J. Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using Auger electron emitters. Br J Cancer, 75: 493-499, 1997.
154. McLaughlin, P. W., Mancini, W. R., Stetson, P. L., Greenberg, H. S., Nguyen, N., Seabury, H., Heidorn, D. B., and Lawrence, T. S. Halogenated pyrimidine sensitization of low dose rate irradiation in human malignant glioma. Int J Radiat Oncol Biol Phys, 26: 637-642, 1993.
155. Lawrence, T. S., David, M. A., Maybaum, J., Stetson, P. L., and Ensminger, W. D. The effect of single versus double-strand substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells. Radiat Res, 123: 192-198, 1990.
156. Lliakis, G., Wang, Y., Pantelias, G. E., and Metzger, L. Mechanism of radiosensitization by halogenated pyrimidines: effect of BrdU on repair of DNA breaks, interphase chromatin breaks, and potentially lethal damage in plateau-phase CHO cells. Radiat Res, 129: 202-211, 1992.
157. Schneiderman, M. H. and Schneiderman, G. S. Radioiododeoxyuridine in cancer therapy. J Nucl Med, 37 (Suppl): 6S-9S, 1996.
158. Shewach, D. S., Ellero, J., Mancini, W. R., and Ensminger, W. D. Decrease in TTP pools mediated by 5-bromo-2'-deoxyuridine exposure in a human glioblastoma cell line. Biochem Pharmacol, 43: 1579-1585, 1992.
159. Van Meir, E. G., Kikuchi, T., Tada, M., Li, H., Diserens, A.-C., Wojcik, B. E., Su Huang, H.-J., Friedmann, T., de Tribolet, N., and Cavenee, W. K. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res, 54: 649-652, 1994.
160. Mariani, G., Di Sacco, S., Volterrani, D., Di Luca, L., Buralli, S., Di Stefano, R., Baranowska-Kortylewicz, J., Bonora, D., Matteucci, F., Ricci, S., Bellina, C. R., Falcone, A., Salvadori, P. A., Mosca, F., Adelstein, S. J., and Kassis, A. I. Tumor targeting by intra-arterial infusion of 5-[¹²³I]iodo-2'-deoxyuridine in patients with liver metastases from colorectal cancer. J Nucl Med, 37 (Suppl): 22S-25S, 1996.
161. Macapinlac, H. A., Kemeny, N., Daghighian, F., Finn, R., Zhang, J., Humm, J., Squire, O., and Larson, S. M. Pilot clinical trial of 5-[¹²⁵I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver. J Nucl Med, 37 (Suppl): 25S-29S, 1996.
162. Tsujinaka, T., Kishibuchi, M., Iijima, S., Yano, M., and Monden, M. Nucleotides and intestine. JPEN J Parenter Enteral Nutr, 23 (Suppl): 74s-77s, 1999.
163. Grimble, G. K. and Westwood, O. M. Nucleotides as immunomodulators in clinical nutrition. Curr Opin Clin Nutr Metab Care, 4: 57-64, 2001.
164. Heyland, D. K., Novak, F., Drover, J. W., Jain, M., Su, X., and Suchner, U. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA, 286: 944-953, 2001.
165. Kulkarni, A. D., Rudolph, F. B., and Van Buren, C. T. The role of dietary sources of nucleotides in immune function: a review. J Nutr, 124: 1442S-1446S, 1994.
166. Matsumoto, Y., Adjei, A. A., Yamauchi, K., Kise, M., Nakasone, Y., Shinagawa, Y., Yokoyama, H., and Yamamoto, S. A mixture of nucleosides and nucleotides increases bone marrow cell and peripheral neutrophil number in mice infected with methicillin-resistant Staphylococcus aureus. J Nutr, 125: 817-822, 1995.
167. Bueno, J., Torres, M., Almendros, A., Carmona, R., Nunez, M. C., Rios, A., and Gil, A. Effect of dietary nucleotides on small intestinal repair after diarrhoea. Histological and ultrastructural changes. Gut, 35: 926-933, 1994.
168. Sanderson, I. R. and He, Y. Nucleotide uptake and metabolism by intestinal epithelial cells. J Nutr, 124 (Suppl): 131S-137S, 1994.
169. Nunez, M. C., Ayudarte, M. V., Morales, D., Suarez, M. D., and Gil, A. Effect of dietary nucleotides on intestinal repair in rats with experimental chronic diarrhea. JPEN J Parenter Enteral Nutr, 14: 598-604, 1990.
170. Iwasa, Y., Iwasa, M., Ohmori, Y., Fukutomi, T., and Ogoshi, S. The effect of the administration of nucleosides and nucleotides for parenteral use. Nutrition, 16: 598-602, 2000.
171. Walsh, M. J., Sanchez-Pozo, A., and Leleiko, N. S. A regulatory element is characterized by purine-mediated and cell-type-specific gene transcription. Mol Cell Biol, 10: 4356-4364, 1990.
172. Weber, G. Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture. Cancer Res, 43: 3466-3492, 1983.
173. He, Y., Chu, S. H., and Walker, W. A. Nucleotide supplements alter proliferation and differentiation of cultured human (Caco-2) and rat (IEC-6) intestinal epithelial cells. J Nutr, 123: 1017-1027, 1993.
174. Mairs, R. J., Wideman, C. L., Angerson, W. J., Whateley, T. L., Reza, M. S., Reeves, J. R., Robertson, L. M., Neshasteh-Riz, A., Rampling, R., Owens, J., Allan, D., and Graham, D. I. Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model. Br J Cancer, 81: 74-80, 2000.
175. Kim, J. H., Kim, S. H., and Eidinoff, L. Cell viability and nucleic acid metabolism after exposure of HeLa cells to excess thymidine and deoxyadenosine. Biochem pharmacol, 14: 1821-1829, 1965.
176. Grimble, G. K., Malik, S. B., and Boza, J. J. Methods for measuring tissue RNA turnover. Curr Opin Clin Nutr Metab Care, 3: 399-408, 2000.
177. Carver, J. D. Dietary nucleotides: effects on the immune and gastrointestinal systems. Acta Paediatr, 88 (Suppl): 83-88, 1999.
178. Savaiano, D. A., Ho, C. Y., Chu, V., and Clifford, A. J. Metabolism of orally and intravenously administered purines in rats. J Nutr, 110: 1793-1804, 1980.
179. Liu, M. P., Beigelman, L., Levy, E., Handschumacher, R. E., and Pizzorno, G. Discrete roles of hepatocytes and nonparenchymal cells in uridine catabolism as a component of its homeostasis. Am J Physiol, 274: G1018-G1023, 1998.
180. Wester, H. J., Herz, M., Weber, W., Heiss, P., Senekowitsch-Schmidtke, R., Schwaiger, M., and Stocklin, G. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med, 40: 205-212, 1999.
181. Iuchi, T., Iwadate, Y., Namba, H., Osato, K., Saeki, N., Yamaura, A., and Uchida, Y. Glucose and methionine uptake and proliferative activity in meningiomas. Neurol Res, 21: 640-644, 1999.
182. Ogawa, T., Miura, S., Murakami, M., Iida, H., Hatazawa, J., Inugami, A., Kanno, I., Yasui, N., Sasajima, T., and Uemura, K. Quantitative evaluation of neutral amino acid transport in cerebral gliomas using positron emission tomography and fluorine-18 fluorophenylalanine. Eur J Nucl Med Mol Imaging, 23: 889-895, 1996.
183. Gorisse, M. C., Desoize, B., Carpentier, Y., and Nguyen, T. D. [In vivo evaluation of potential doubling time (Tpot) of tumors by flow cytometry: practical difficulties and possible solutions] in French. Bull Cancer, 83: 825-834, 1996.
184. Tjuvajev, J. G., Macapinlac, H. A., Daghighian, F., Scott, A. M., Ginos, J. Z., Finn, R. D., Kothari, P., Desai, R., Zhang, J., and Beattie, B. Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. J Nucl Med, 35: 1407-1417, 1994.
185. Panyutin, I. G., Winters, T. A., Feinendegen, L. E., and Neumann, R. D. Development of DNA-based radiopharmaceuticals carrying Auger-electron emitters for anti-gene radiotherapy. Q J Nucl Med, 44: 256-267, 2000.
186. Lu, L., Bergstrom, M., Fasth, K. J., and Langstrom, B. Synthesis of [76Br]bromofluorodeoxyuridine and its validation with regard to uptake, DNA incorporation, and excretion modulation in rats. J Nucl Med, 41: 1746-1752, 2000.
187. Borbath, I., Gregoire, V., Bergstrom, M., Laryea, D., Langstrom, B., and Pauwels, S. Use of 5-[(76)Br]bromo-2'-fluoro-2'-deoxyuridine as a ligand for tumour proliferation: validation in an animal tumour model. Eur J Nucl Med Mol Imaging, 29, 2002.
188. Shields, A. F., Grierson, J. R., Dohmen, B. M., Machulla, H.-J., Stayanoff, J. C., Lawhorn-Crews, J. M., Obradovich, J. E., Muzik, O., and Mangner, T. J. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med, 4: 1334-1336, 1998.
189. Buck, A. K., Schirrmeister, H., Hetzel, M., Von Der Heide, M., Halter, G., Glatting, G., Mattfeldt, T., Liewald, F., Reske, S. N., and Neumaier, B. 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res, 62: 3331-3334, 2002.
190. Wolff, J. Perchlorate and the thyroid gland. Pharmacol Rev, 50: 89-105, 1998.
191. Berlin, J., Merrick, H. W., Smith, T. J., and Lerner, H. Phase II evaluation of treatment of complete resection of hepatic metastases from colorectal cancer and adjuvant hepatic arterial infusion of floxuridine: an Eastern Cooperative Oncology Group Study (PB083). Am J Clin Oncol, 22: 291-293, 1999.
192. Focan, C., Levi, F., Kreutz, F., Focan-Henrard, D., Lobelle, J. P., Adam, R., Dallemagne, B., Jehaes, C., Markiewicz, S., Weerts, J., Bismuth, H., Jasmin, C., and Misset, J. L. Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. Anticancer Drugs, 10: 385-392, 1999.
193. Pluen, A., Boucher, Y., Ramanujan, S., McKee, T. D., Gohongi, T., di Tomaso, E., Brown, E. B., Izumi, Y., Campbell, R. B., Berk, D. A., and Jain, R. K. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A, 98: 4628-4633, 2001.
194. Yamauchi, K., Komatsu, T., Kulkarni, A. D., Ohmori, Y., Minami, H., Ushiyama, Y., Nakayama, M., and Yamamoto, S. Glutamine and arginine affect Caco-2 cell proliferation by promotion of nucleotide synthesis. Nutrition, 18: 329-333, 2002.
195. Van Buren, C. T., Kulkarni, A. D., and Rudolph, F. B. The role of nucleotides in adult nutrition. J Nutr, 124 (Suppl): 160S-164S, 1994.
196. Beale, R. J., Bryg, D. J., and Bihari, D. J. Immunonutrition in the critically ill: a systematic review of clinical outcome. Crit Care Med, 27: 2799-2805, 1999.
197. Heys, S. D., Walker, L. G., Smith, I., and Eremin, O. Enteral nutritional supplementation with key nutrients in patients with critical illness and cancer: a meta-analysis of randomized controlled clinical trials. Ann Surg, 229: 467-477, 1999.
198. Senkal, M., Kemen, M., Homann, H. H., Eickhoff, U., Baier, J., and Zumtobel, V. Modulation of postoperative immune response by enteral nutrition with a diet enriched with arginine, RNA, and omega-3 fatty acids in patients with upper gastrointestinal cancer. Eur J Surg, 161: 115-122, 1995.
199. Yamamoto, S., Adjei, A. A., Yokoyama, H., Ahagon, K., Chang, Y. C., and Imamura, T. Nucleoside-nucleotide mixture and its components and response to methicillin-resistant Staphylococcus aureus infection in mice. Nutrition, 9: 524-527, 1993.
200. Matsumoto, Y., Adjei, A. A., Yamauchi, K., Kise, M., Yokoyama, H., Shinagawa, Y., and Yamamoto, S. Nucleoside-nucleotide mixture increases peripheral neutrophils in cyclophosphamide-induced neutropenic mice. Nutrition, 11: 296-299, 1995.
201. Adjei, A. A., Morioka, T., Ameho, C. K., Yamauchi, K., Kulkarni, A. D., Al-Mansouri, H. M., Kawajiri, A., and Yamamoto, S. Nucleoside-nucleotide free diet protects rat colonic mucosa from damage induced by trinitrobenzene sulphonic acid. Gut, 39: 428-433, 1996.
202. Goody, H. E. and Ellem, K. A. Nutritional effects on precursor uptake and compartmentalization of intracellular pools in relation to RNA synthesis. Biochim Biophys Acta, 383: 30-39, 1975.
203. Tsujinaka, T., Iijima, S., Kido, Y., Homma, T., Ebisui, C., Kan, K., Imamura, I., Fukui, H., and Mori, T. Role of nucleosides and nucleotide mixture in intestinal mucosal growth under total parenteral nutrition. Nutrition, 9: 532-535, 1993.
204. Usami, M. and Saitoh, Y. The effect of a nucleotide-nucleoside solution on hepatic regeneration in rats after partial hepatectomy and in primary monolayer culture of hepatocytes. Nutrition, 13: 365-368, 1997.

8. Bibliographie

9. Liste des publications personnelles